Atrium Therapeutics Inc.

RNA | NASDAQ

Price Alert Chart Builder DCF Calculator

$8.27

+$0.01 (+0.12%)

At close: Oct 30, 2026, 4:00 PM ET

$8.39

+$0.12 (+1.45%)

Pre-market: Nov 2, 2026, 7:36 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $141.46M

Enterprise Value $-121.06M

Beta 0.37

Average Volume 257.23K

Shares Outstanding (Diluted) 17.11M

Shares Change YoY N/A

Institutional Ownership 84.59%

Exchange NASDAQ

ISIN US04965N1046

Price Performance

Price Change 1M -0.1%

Price Change 3M -27.1%

Price Change 6M -38.4%

Price Change YTD N/A

Price Change 1Y N/A

Price Change 3Y N/A

Price Change 5Y N/A

1M CAGR (ann.) -7.6%

1Y CAGR (ann.) N/A

5Y CAGR (ann.) N/A

All-Time CAGR -57.8%

Valuation

PE Ratio -2.15

Forward PE N/A

PEG Ratio 0.03

Forward PEG 0.36

PS Ratio 6.02

Forward PS 53.00

PB Ratio 0.66

P/FCF Ratio -2.47

P/Adj. FCF Ratio -2.32

P/OCF Ratio -2.60

EV/Sales -5.15

EV/EBIT 1.26

EV/EBITDA 1.27

EV/FCF 2.11

Earnings Yield -46.5%

FCF Yield -40.5%

Adj. FCF Yield -43.0%

Financial Health

Net Cash $262.53M

Total Debt $1.68M

Cash & Short-Term Investments $264.21M

Total Assets $280.51M

Current Ratio 8.73

Quick Ratio 8.73

Debt / Equity Ratio 0.01

Debt / EBITDA -0.02

Debt / FCF -0.03

OCF / Debt -32.28

Interest Coverage 0.00

Altman Z-Score 1.25

Piotroski F-Score 1

Margins & Profitability

Gross Profit Margin 97.9%

Operating Profit Margin -410.2%

EBITDA Margin -404.6%

Net Profit Margin -396.5%

FCF Margin -244.0%

Adj. FCF Margin -259.1%

SBC / Revenue 15.1%

SBC Impact (per share) -6.2%

Returns

Return on Assets -33.2%

Return on Equity -42.9%

Return on Invested Capital -38.4%

Return on Capital Employed -38.7%

Return on Tangible Assets -33.2%

Analyst Forecasts

Analyst Rating Hold

Analyst Count 2

EPS Growth Next 3Y -6.4%

Revenue Growth Next 3Y 309.1%

Earnings Date Nov 12, 2026

EPS Estimate (next Q) -$0.81

EPS Growth Est (next Q) N/A

Revenue Est (next Q) $15M

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $21.25

Price Target Upside 157.0%

Cash Flow

Operating Cash Flow $-54.32M

Free Cash Flow $-57.33M

Adj. Free Cash Flow $-60.89M

FCF Per Share -$3.35

OCF Per Share -$3.18

OCF/S Ratio -231.2%

Income Statement

Revenue $23.5M

Gross Profit $23M

Operating Income $-96.4M

EBITDA $-95.06M

Net Income $-93.18M

EPS (Diluted) -$3.85

Revenue / Employee $45.98K

Profit / Employee $-182.34K

Employees 511